4th UpDate on Hepatology

Size: px
Start display at page:

Download "4th UpDate on Hepatology"

Transcription

1 4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN

2 4 th UpDate on Hepatology Course, Bucharest 6 th -7 th April 2017 Hepatology 2017 A panoramic view" 6 April Registration & Welcome Introduction: Liana Gheorghe Challenging issues in hepatitis B Chair: Pietro Lampertico, Mircea Diculescu How to manage HBV infected patients in 2017? Pietro Lampertico, Milan, Italy Hepatitis B reactivation prevention and therapy Adrian Goldiş, Timişoara, România Long-term impact of antiviral therapy in chronic hepatitis B Marcel Tanţău, Cluj-Napoca, România Recent advances in HDV therapy Jerzy Jaroszewicz, Bialystok, Poland Alcoholic and non-alcoholic liver disease Chair: Vlad Ratziu Old and new biomarkers for NASH Mona Munteanu, Paris, France The impact of new multi-parametric measures of fatty liver by ultrasound and magnetic resonance in clinical practice Ferrucio Bonino, Pisa, Italy What is the current medical management of NASH and future perspectives Ioan Sporea, Timişoara, România Treatment of alcoholic hepatitis Vlad Ratziu, Paris, France Satellite Symposium BMS Speaker: Pietro Lampertico, Milan, Italy Lunch

3 Challenging issues in hepatitis C Chair: Nancy Reau, Ioan Sporea HCV treatment of GT-1 patients now and in the future. Strategies for simplification Liana Gheorghe, Bucharest, România Treatment of HCV special populations: decompensated cirrhosis and chronic kidney disease Susanne Beckebaum, Muenster, Germany Impact of therapy on hepatic and extrahepatic manifestation of chronic HCV infection Nancy Reau, Chicago, USA Hepatocellular carcinoma in patients with HCV liver cirrhosis treated with direct-acting antivirals (DAAs) Speranţa Iacob, Bucharest, România Coffee Break and Poster Viewing Satellite Symposium AbbVie Parallel Case-based Workshops 1. Susanne Beckebaum, Speranţa Iacob: Management of chronic hepatitis C 2. Cristian Gheorghe, Carol Stanciu: Special issues in liver cirrhosis 3. Ioan Sporea, Vlad Ratziu: Alcoholic & non-alcoholic fatty liver disease Dinner 7 April Hepatocellular carcinoma Chair: Patrizia Burra Combination and dynamics of serum biomarkers to personalized surveillance, diagnosis and management of hepatocellular carcinoma Maurizia Brunetto, Pisa, Italy Diagnosis of hepatocellular carcinoma by imaging : How can we improve accuracy? Ioana Lupescu, Bucharest, România Radiofrequency ablation: who should be treated, how to be done and response evaluation Zeno Spârchez, Cluj-Napoca, România

4 q Transarterial chemoembolization: who should be treated, how to be done and response evaluation Mugur Grasu, Bucharest, România Transplantation for hepatocellular carcinoma Patrizia Burra, Padova, Italy Systemic therapy and immunotherapy for advanced hepatocellular carcinoma Markus Peck-Radosavljevic, Austria Coffee Break and Poster Viewing Special issues in cirrhosis Chair: Vito Cicinnati, Cristian Gheorghe Acute on chronic liver disease Anca Trifan, Iaşi, România Use of betablockers in decompensated cirrhosis Cristina Cijevschi, Cătălina Mihai, Iaşi, România Cirrhotic coagulopathy: practical aspects Dana Tomescu, Bucharest, România q Satellite Symposium MSD Lunch q Satellite Symposium Gilead Original Research Forum Chair: Costică Aloman, Răzvan Iacob Arguments for hepatocyte reprogramming during advanced liver fibrosis background for hepatocarcinogenesis Răzvan Iacob, Bucharest, România Targeting mononuclear phagocytes development in alcoholic liver injury: pathological and immunological pathways Costică Aloman, Chicago, USA The metabolic profile of decompensation in patients with cirrhosis Bogdan Procopeţ, Cluj-Napoca, România

5 The role of combined liver and spleen elastometry for the prediction of the response to therapy in severe alcoholic hepatitis Horia Ştefănescu, Cluj-Napoca, România Early-TIPS improves survival in high-risk variceal bleeders Results of a multicenter variceal bleeding observational study Virginia Hernandez Gea, Barcelona, Spain Coffee Break q Satellite Symposium Alfa Wassermann Gut Dysbiosis and Inflammation in Cirrhosis and Hepatic Encephalopathy: Role for Microbiota-directed Therapies Speaker: Carmelo Scarpignato, Parma, Italy Autoimmune and genetic liver disease Chair: Susanne Beckebaum, Carol Stanciu Management of autoimmune liver disease in 2017 Vito Cicinnati, Muenster, Germany Management of cholestatic liver diseases in 2017 Iulia Simionov, Bucharest, România Wilson disease: from genetics to therapy Hartmut Schmidt, Muenster, Germany Closing and Poster Awards

PRELIMINARY SCIENTIFIC PROGRAM :50 Meet the experts- Molecular mechanisms in IBD from basic science to therapy. Franco-Romanian Meeting

PRELIMINARY SCIENTIFIC PROGRAM :50 Meet the experts- Molecular mechanisms in IBD from basic science to therapy. Franco-Romanian Meeting PRELIMINARY SCIENTIFIC PROGRAM RCCC Annual Meeting 27th-29th of SEPEMBER 2018 Thursday 27 th of September 2018 7.30-8.00 Registration 8.00-9:50 Meet the experts- Molecular mechanisms in IBD from basic

More information

6 th UpDate. on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease

6 th UpDate. on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease 6 th UpDate on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease COURSE DIRECTORS Liana GHEORGHE Anca TRIFAN Ioan SPOREA 5 th - 6 th April 2019 Bucharest Crowne Plaza

More information

SCIENTIFIC PROGRAM. The First Franco-Romanian Meeting

SCIENTIFIC PROGRAM. The First Franco-Romanian Meeting SCIENTIFIC PROGRAM RCCC Annual Meeting 27 th -29 th of September 2018 The First Franco-Romanian Meeting Thursday 27 th of September 2018 7.30-8.15 Registration 8.15-9:45 Meet the experts The therapeutic

More information

PROGRAMME AT A GLANCE

PROGRAMME AT A GLANCE PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver

More information

The 10th National Symposium on Inflammatory Bowel Diseases

The 10th National Symposium on Inflammatory Bowel Diseases 1958 The 10 th National Symposium on Inflammatory Bowel Diseases Crowne Plaza Hotel, Bucharest, 27 th - 29 th of September 2018 The First Franco- Romanian Meeting Program www.rccc-congress.ro office.rccc@gmail.com

More information

Dear Colleagues and Friends of the pancreas,

Dear Colleagues and Friends of the pancreas, 3rdP ANCREATI CDI SEASECOURSE 4th E USWORKSHOPi npancreati CDI SEASES www. wor k s hoppanc r e as. r o r e. www. panc as r o COURSEDI RECTORS Cr i s t i angheor ghe Mi r c eadi c ul es c u I r i nelpopes

More information

SCIENTIFIC PROGRAM Pharma Symposium Takeda: Changing the Game in IBD. Speakers: Bogdan Mateescu, Lucian Negreanu

SCIENTIFIC PROGRAM Pharma Symposium Takeda: Changing the Game in IBD. Speakers: Bogdan Mateescu, Lucian Negreanu SCIENTIFIC PROGRAM RCCC Annual Meeting 28 th -30 th of SEPEMBER 2017 Thursday 28 th of September 2017 ECCO educational workshop 17.30-18.30 Pharma Symposium Takeda: Changing the Game in IBD. Speakers:

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Dear colleagues and friends,

Dear colleagues and friends, Dear colleagues and friends, After the last year s success, I am delighted to welcome you to the 2017 Bucharest PancreaticFest, which will take place at the Crowne Plaza Hotel in Bucharest, from the 8th

More information

Angelos Hatzakis. 10th Paris Hepatology Conference

Angelos Hatzakis. 10th Paris Hepatology Conference Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology

More information

Liver transplantation: an ongoing challenge

Liver transplantation: an ongoing challenge Scientific Symposium Liver transplantation: an ongoing challenge May 19 th, 2010 11.00 am - 6.45 pm Complesso Monumentale di Santa Chiara, Napoli Sala Maria Cristina Scientific Symposium Liver transplantation:

More information

From Medical Treatment to Liver Transplantation PROGRAM NAFLD/NASH CONSENSUS CONFERENCE 2018

From Medical Treatment to Liver Transplantation PROGRAM NAFLD/NASH CONSENSUS CONFERENCE 2018 www.ilts.org From Medical Treatment to Liver Transplantation PROGRAM NAFLD/NASH Course Directors Patrizia Burra, MD, PhD University of Padova Padova, Italy Marina Berenguer, MD University and Polytechnic

More information

RCCC Romanian Crohn`s

RCCC Romanian Crohn`s RCCC Romanian Crohn`s and Colitis Club 8 th National Symposium on Inflammatory Bowel Diseases 29 th of September - 1 st of October 2016 Crowne Plaza Bucharest, Romania President Mircea Diculescu Organizing

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice 3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,

More information

International Society of Microbiota

International Society of Microbiota Targeting Microbiota World Congress 2018 1 Targeting Microbiota World Congress 2018 2 Dear Colleagues, On behalf of the International Society of Microbiota, we are pleased to inform you that the 6th World

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

HIV and HCV coinfection - Barriers in Central and Eastern Europe

HIV and HCV coinfection - Barriers in Central and Eastern Europe HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical

More information

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

THE ROMANIAN HEPATITIS ACTION PAPER

THE ROMANIAN HEPATITIS ACTION PAPER 1 THE ROMANIAN HEPATITIS ACTION PAPER PRODUCED BY: EUROPEAN LIVER PATIENTS ASSOCIATION APAH-RO WRITTEN BY: ACHIM KAUTZ, POLICY DIRECTOR, ELPA CRISTINA ENESCU, REPRESENTATIVE, APAH-RO LILYANA CHAVDAROVA,

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

P R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go?

P R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go? P R O G R A M Course Day 1, Friday November 2, 2018 08:30 08:00 Official Opening Welcome Address 08:30 08:35 08:35 08:40 08:40 08:45 08:45 08:50 Jakob Izbicki (Germany), EFISDS President T. Seufferlein

More information

KIDNEY LIVER MEETS FINAL PROGRAM KIDNEY MEETS LIVER. When the excellence in renal and liver medicine come together. XXXXXXX

KIDNEY LIVER MEETS FINAL PROGRAM KIDNEY MEETS LIVER. When the excellence in renal and liver medicine come together. XXXXXXX XXXXXXX When the excellence in renal and liver medicine come together. 1 COMITATI SCIENTIFIC PROGRAM Organizing Committee Prof. Michel Jadoul Chief Service de Nephrologie Clinique Universitaire Saint-Luc

More information

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Progression of the disease. Heiner Wedemeyer

Progression of the disease. Heiner Wedemeyer Progression of the disease Heiner Wedemeyer Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Eiger, Gilead, ITS, JJ/Janssen-Cilag, Medgenics,

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

RJGE VOL.12, NR.2, JUNE 2003

RJGE VOL.12, NR.2, JUNE 2003 RJGE VOL.12, NR.2, JUNE 2003 ORIGINAL PAPER Correlation of sicam-1 and svcam-1 Level with Biochemical, Histological and Viral Findings in Chronic Hepatitis C after Interferon-a+ Ribavirin Therapy Corina

More information

Hepatology For The Nonhepatologist

Hepatology For The Nonhepatologist Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able

More information

EASL HCC SUMMIT 2018 FROM BASIC TO CLINICAL RESEARCH: HOW TO IMPROVE HCC CLINICAL CARE? 01 03, MARCH 2018 GENEVA, SWITZERLAND

EASL HCC SUMMIT 2018 FROM BASIC TO CLINICAL RESEARCH: HOW TO IMPROVE HCC CLINICAL CARE? 01 03, MARCH 2018 GENEVA, SWITZERLAND EASL HCC SUMMIT 2018 FROM BASIC TO CLINICAL RESEARCH: HOW TO IMPROVE HCC CLINICAL CARE? 01 03, MARCH 2018 GENEVA, SWITZERLAND SCIENTIFIC ORGANISING COMMITTEE Alejandro Forner, Spain Peter Galle, Germany

More information

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. Robert J. de Knegt, Erasmus MC, Rotterdam r.deknegt@erasmusmc.nl Disclosures

More information

Liver transplant: what is left after the viruses

Liver transplant: what is left after the viruses Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT. 1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of

More information

Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy

Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy Liana Gheorghe 1, Speranta Iacob 1, Razvan Iacob 1, Gabriela Smira 1, Corina Pietrareanu 1, Doina

More information

Programme September 2017 Prague, Czech Republic

Programme September 2017 Prague, Czech Republic Programme 25 27 September 2017 Prague, Czech Republic Programme committee chairs Ladislav Dušek (Czech Republic) Director of the Institute of Health Information And Statistics of the Czech Republic Monday,

More information

RJGE VOL.11, NR.1, MARCH 2002

RJGE VOL.11, NR.1, MARCH 2002 RJGE VOL.11, NR.1, MARCH 2002 Original papers Calculation of Esophageal Variceal Wall Tension by Ultrasonic Microprobe and Noninvasive Pressure Measurements Zhu Saihong, Liu Xunyang, Huang Feizhou, Nei

More information

HCV elimination : lessons from Scotland

HCV elimination : lessons from Scotland HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

Autoimmune Hepatitis Events Easl

Autoimmune Hepatitis Events Easl Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

15 & 16 January International Conference on the Management of Liver Diseases. Organised by Pr Patrick Marcellin

15 & 16 January International Conference on the Management of Liver Diseases. Organised by Pr Patrick Marcellin 15 & 16 January 2018 PARIS - Palais des Congrès International Conference on the Management of Liver Diseases Organised by Pr Patrick Marcellin Organising Committee Blaise Kutala, Monelle Muntlak Hôpital

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Screening for Portal Hypertension in Cirrhosis

Screening for Portal Hypertension in Cirrhosis Screening for Portal Hypertension in Cirrhosis MASSIMO PINZANI, MD, PhD, FRCP Sheila Sherlock Chair of Hepatology UCL Institute for Liver and Digestive Health Royal Free Hospital, London, UK m.pinzani@ucl.ac.uk

More information

Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery. Scientific Program

Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery. Scientific Program Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery Scientific Program Thursday, October 30 th 13:30 13:45 Official Opening Welcome

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

HCC and the Hallmarks of Cancer: steps towards novel therapeutic strategies

HCC and the Hallmarks of Cancer: steps towards novel therapeutic strategies EASL HCC SUMMIT 2017 2-5 February 2017, Geneva, Switzerland Scientific Committee: Basic Programme: Tom Luedde, Germany Helen Reeves, United Kingdom Clinical Programme: Alejandro Forner, Spain Franco Trevisani,

More information

WORLDWIDE EPIDEMIOLOGY OF NASH

WORLDWIDE EPIDEMIOLOGY OF NASH WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),

More information

Hepatitis C in Disclosures

Hepatitis C in Disclosures Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

Original papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş

Original papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş Original papers Med Ultrason 2013, Vol. 15, no. 2, 111-115 DOI: 10.11152/mu.2013.2066.152.is1ir2 Are different cut-off values of liver stiffness assessed by Transient Elastography according to the etiology

More information

SCIENTIFIC PROGRAMME

SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME Tuesday, May 25 th 2017 08.30-09.30 ORAL PRESENTATIONS (HALL 1) Chairpersons : G. Baltagiannis, E. Vezali 08.30-09.30 Oral Presentations HALL 2) Chairpersons: E. Dimou, O. Giouleme

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD)

Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD) Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD) Dr. H. Razavi May 31, 2017 First European NASH NAFLD Summit Disclosure: This work with funded by a multi-sponsored research grant from Intercept,

More information

Antiviral Therapy and Liver Cancer

Antiviral Therapy and Liver Cancer Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention

More information

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy

New York State HCV Provider Webinar Series. Side Effects of Therapy New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related

More information

Hepatitis C Policy Discussion

Hepatitis C Policy Discussion Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Organized by. Scientific comittee

Organized by. Scientific comittee July 11 & 12, 2019 Institut Pasteur Organized by Arun Sanyal Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA Lawrence Serfaty Hôpital Hautepierre Hôpitaux Universitaires de

More information

10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS

More information

Professor Norbert Bräu

Professor Norbert Bräu Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST

More information

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus 231-727-5575/231-728-4054 Fax » CURABLE» Most common blood borne infection» 75-85% of those exposed will develop chronic infection»

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Hepatitis C - results in real life

Hepatitis C - results in real life Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or

More information

Saturday, 5 December 2015 Ramada Parc Hotel, Conference Hall 1

Saturday, 5 December 2015 Ramada Parc Hotel, Conference Hall 1 Saturday, 5 December 2015 Ramada Parc Hotel, Conference Hall 1 08.30-08.40 Opening Ceremony 08.40-10.40 Session I Multidisciplinary Approach of Metabolic Syndrome Ciprian Duţă (Timişoara, Romania) Nicolae

More information

Supplementary Digital Content

Supplementary Digital Content Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy

More information

Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection

Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Liz Highleyman Produced in collaboration with hivandhepatitis.com Published: 28 October 2015 Jump to Trends

More information

Seminars ELECTRONEUROMYOGRAPHY SEMINAR MODULE 12 IN CONJUNCTION WITH

Seminars ELECTRONEUROMYOGRAPHY SEMINAR MODULE 12 IN CONJUNCTION WITH Seminars Department of Neurosciences University of Medicine and Pharmacy Iuliu Hatieganu Cluj-Napoca Romania IN CONJUNCTION WITH ELECTRONEUROMYOGRAPHY SEMINAR MODULE 12 NOVEMBER 11 TH - 12 TH 2016 RONEURO

More information

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic

More information

LIVER DISEASE IN RESOURCE LIMITED SETTINGS

LIVER DISEASE IN RESOURCE LIMITED SETTINGS LIVER DISEASE IN RESOURCE LIMITED SETTINGS MAY 29-30, 205 BUCHAREST, ROMANIA PROGRAMME & ABSTRACTS www.easl.eu/bucharest205 www.easl.eu CONTENTS Welcome Message 3 Committees 4 Acknowledgements / Sponsors

More information

9th Paris Hepatitis Conference

9th Paris Hepatitis Conference 9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units

More information

HEPATITIS B: WHO AND WHEN TO TREAT?

HEPATITIS B: WHO AND WHEN TO TREAT? HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of

More information

Volume 26 Supplement

Volume 26 Supplement JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES - 06, Volume 6, Supplement 3 Volume 6 Supplement 3 07 Medical University Press Cluj-Napoca, Romania Cover design: Istvàn Feleki ISSN: 457-3876, ISSN-L 457-3876

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

The future of liver transplantation for viral hepatitis

The future of liver transplantation for viral hepatitis The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with

More information

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

EULIS - PNL WORKSHOP 1-3 November 2018 Timisoara, Romania Programme

EULIS - PNL WORKSHOP 1-3 November 2018 Timisoara, Romania Programme https://eulispnlworkshop.org EULIS - PNL WORKSHOP 1-3 November 2018 Timisoara, Romania Programme Welcome Address Honourable guests, distinguished colleagues, dear friends, Welcome to the PNL Workhop organized

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM

More information

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated

More information

International Hepatitis Symposium Heidelberg

International Hepatitis Symposium Heidelberg 16 th May 18 th May 2018 International Hepatitis Symposium Heidelberg Ralf Bartenschlager s 60 th Birthday Symposium (16 th ) AND International Symposium of the TRR179 (17 th to 18 th ) Confirmed Speakers:

More information

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic

More information

Organized by: Division of Hepatology and Gene Therapy

Organized by: Division of Hepatology and Gene Therapy Organized by: Division of Hepatology and Gene Therapy WELCOME MESSAGE Pamplona, June 2004 Dear colleagues, Welcome to Frontiers 2004! This new edition of Frontiers is an especial one since it coincides

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma. Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital

More information